Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer

CONCLUSION: A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.PMID:37725049 | DOI:10.1093/oncolo/oyad258

Source: The Oncologist - September 19, 2023 Category: Cancer & Oncology Authors: Juan Luis Gomez Marti Azadeh Nasrazadani Ying Ding Daniel Normolle Adam M Brufsky Source Type: research